Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07049328 · ClinicalTrials.gov registry record · Phase 1
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
A Phase 1 study of Alopecia Areata (AA), sponsored by HCW Biologics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT07049328: Recruiting Phase 1 study of Alopecia Areata (AA), sponsored by HCW Biologics.
NCT07049328 is a Phase 1 study of Alopecia Areata (AA) that is actively recruiting participants, run by HCW Biologics. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07049328, a Phase 1 study of Alopecia Areata (AA), is actively recruiting participants, sponsored by HCW Biologics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)
Primary Outcome
Evaluate the safety profile of HCW9302 monotherapy in subjects with Alopecia Areata (AA), based on the incidence, type, and severity of adverse events (AEs) classified according to MedDRA.
Conditions Studied
Interventions
- DRUG HCW9302, an IL-2 fusion protein
Study Locations (2)
Florida
- James A. Haley Veterans' Hospital - Tampa
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-08-16 |
| Est. Completion | 2026-12-15 |
| Phase | Phase 1 |
What NCT07049328 shows while recruiting
NCT07049328 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Alopecia Areata (AA) appearing as the primary indexed condition, and to 1 intervention - of which HCW9302, an IL-2 fusion protein is the first listed.
NCT07049328 reports a single indexed study location in Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT07049328 about?
NCT07049328 is a clinical study titled "HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata". This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)
What is the current status of trial NCT07049328?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-08-16. Estimated completion is 2026-12-15.
What conditions does trial NCT07049328 study?
This clinical trial studies the following conditions: Alopecia Areata (AA).
What interventions are being tested in trial NCT07049328?
The interventions under investigation include: HCW9302, an IL-2 fusion protein (DRUG).
Who is sponsoring clinical trial NCT07049328?
This trial is sponsored by HCW Biologics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07049328 being conducted?
This trial has 2 study locations across Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata (AA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07049328's enrollment target sits among peer trials
30 1333rd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI